PMC10171758_01
F-18 FDG PET/CT MIP image (a) shows metabolically active lymphadenopathy and pancreas and liver lesions. Axial section CT and fused PET/CT images of the neck (b and c) show cervical lymphadenopathy with max SUV: 37.6. Images (d and e) show pancreas body involvement with max SUV: 17.4. Images (f and g) show hypodense lesion involving liver with max SUV: 38.2. MIP: Maximum intensity projection, F-18 FDG PET/CT: Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography
IJNM-38-59-g001.jpg
PMC10171758_01_IJNM-38-59-g001.jpg
F1
Metabolically active 3.5 cm x 4.1 cm lesions involving segment V of the right lobe of the liver were noted and metabolically active 6.8 cm x 6.6 cm x 7.8 cm conglomerate lymph nodal mass involving left level Ib, II lymph nodes along with peripancreatic, paraaortic, and aortocaval lymph nodes [Figure 1].
H and E 100X image (a) showing tangiblebody macrophages having cellular debris and benign histiocytes containing abundant, clear cytoplasm dispersed among the background of basophilic tumor cells. IHC 100X images (b and c) showing CD19 and CD20 positivity. IHC: Immunohistochemistry
IJNM-38-59-g002.jpg
PMC10171758_01_IJNM-38-59-g002.jpg
F2
Further immunohistochemistry (IHC) examination revealed tumor cells that were positive for CD20, BCL 6, and CD10 with a Ki67 index of 90% suggestive of BL [Figure 2].